Heart Failure: Current Status of Sacubitril Valsartan ARNI Heart Failure

Heart failure once sets in, runs a malignant progression with a very high morbidity and mortality. The five year mortality is to the tune of 50%, a figure higher than most of the malignant lesions. The conventional therapy of ACE/ARB, beta blockers, MRAs has no doubt shown significant mortality benefit but sacubitril valsartan combination has shown incremental benefit on top of conventional therapy in terms of reduction of cardiovascular deaths and hospitalization of HF.